Ying G. Li
Eli Lilly and Company
21 Papers
177 Citations
Ying G. Li is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Prasugrel & Prasugrel Hydrochloride. The author has an hindex of 17, co-authored 21 publications.
Chat about Author
Papers
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
Ying G. Li,Lan Ni,John T. Brandt,David S. Small,Christopher D. Payne,C. Steven Ernest,Shashank Rohatagi,Nagy A. Farid,Joseph A. Jakubowski,Kenneth J. Winters +9 more
TL;DR: This integrated analysis confirms the findings of earlier individual studies, that prasugrel achieves faster onset of greater extent and more consistent platelet inhibition compared to the approved and higher loading doses of clopidogrel.
60
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Joseph A. Jakubowski,Christopher D. Payne,Govinda Weerakkody,John T. Brandt,Nagy A. Farid,Ying G. Li,Hideo Naganuma,D. Richard Lachno,Kenneth J. Winters +8 more
TL;DR: Prasugrel dose-dependently inhibited ADP-induced platelet aggregation and exhibited higher levels of platelet inhibition than clopidogrel or ASA alone and resulted in additive inhibition of collagen- and TRAP-induced Platelet aggregation.
58
A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis
Joseph A. Jakubowski,Ying G. Li,David S Small,Christopher D. Payne,Molly Tomlin,Junxiang Luo,Kenneth J. Winters +6 more
TL;DR: An integrated analysis supports the findings of earlier individual studies comparing these methodologies that assess platelet function and the VN-P2Y12 “BASE” channel appeared to be susceptible to high levels of P2y12 blockade, which would underestimate the Vn-P 2Y12-reported percent inhibition in individuals who respond well to loading doses of thienopyridines.
54
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Christopher D. Payne,Ying G. Li,John T. Brandt,Joseph A. Jakubowski,David S. Small,Nagy A. Farid,Daniel E. Salazar,Kenneth J. Winters +7 more
TL;DR: Switching directly from clopidogrel MD to either prasugrel LD or MD was well tolerated and resulted in significantly greater levels of platelet inhibition than a clopIDogrel 75 mg MD.
49
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
Nagy A. Farid,Joseph A. Jakubowski,Christopher D. Payne,Ying G. Li,Y Jin,C. S. Ernest,Kenneth J. Winters,John T. Brandt,Daniel E. Salazar,David S. Small +9 more
TL;DR: Dose adjustment should not be necessary when prasugrel is administered with CYP inducers since formation of pr asugrel's active metabolite is not affected by potent enzyme induction with rifampin.
34